Neurelis, Inc. is an innovation-driven neuroscience company providing a highly differentiated approach to target unmet medical needs. Neurelis is focused on the development and commercialization of product candidates for epilepsy and the broader central nervous system (CNS) market. We are built on a foundation of people with a passion for progress in serving the needs of people with epilepsy and those who care for them. Neurelis has reached a milestone in patient care with its first FDA-approved treatment. For further information, please visit our Product Page. For more information about Neurelis, please visit http://www.neurelis.com.